Matthew Thompson, Associate Director, Statistical Programming at Phastar, authored a piece for Clinical Research News on how Real-World Evidence (RWE) is transforming drug development. He explores the benefits of RWE in hybrid trials, patient recruitment, and adaptive designs, as well as the challenges of working with Real-World Data (RWD).
”RWE can allow us to answer questions around population, drug effectiveness, safety and disease characteristics. RWE can help accelerate trial outcomes by enabling hybrid designs, faster recruitment, adaptive trials, and post-market evidence generation. While working with RWD can be challenging, with the correct expertise, we can overcome this and gain a better understanding of real-world treatment patterns and outcomes to help direct future research and patient care. ”